ROSELLI, MARIO

ROSELLI, MARIO  

Dipartimento di Medicina dei sistemi  

Mostra records
Risultati 1 - 20 di 207 (tempo di esecuzione: 0.023 secondi).
Data di pubblicazione Titolo Autore(i) Tipo File
1-ago-2009 A novel K-ras mutation in colorectal cancer. A case report and literature review Palmirotta, R; Savonarola, A; Formica, V; Ludovici, G; Del Monte, G; Roselli, M; Guadagni, F Articolo su rivista
1-gen-2014 A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice Barni, S; Lorusso, V; Giordano, M; Sogno, G; Gamucci, T; Santoro, A; Passalacqua, R; Iaffaioli, V; Zilembo, N; Mencoboni, M; Roselli, M; Pappagallo, G; Pronzato, P Articolo su rivista
1-ago-2001 A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study Guadagni, F; Ferroni, P; Carlini, S; Mariotti, S; Spila, A; Aloe, S; D'Alessandro, R; Carone, M; Cicchetti, A; Ricciotti, A; Venturo, I; Perri, P; Di Filippo, F; Cognetti, F; Botti, C; Roselli, M Articolo su rivista
3-apr-2022 Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review Iannantuono, Gm; Riondino, S; Sganga, S; Roselli, M; Torino, F Articolo su rivista
1-gen-2001 Adjuvant chemotherapy for stage IB non-small cell lung cancer Ambrogi, V; Mariotti, S; Roselli, M; Mineo, Tc Intervento a convegno
1-ago-2013 Aging: an important risk factor in chemotherapy-associated vascular diseases Roselli, M; Guadagni, F; Ferroni, P Articolo su rivista
1-mag-2011 An activated protein C-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients Ferroni, P; Martini, F; Portarena, I; Grenga, I; Riondino, S; La Farina, F; Laudisi, A; Roselli, M; Guadagni, F Articolo su rivista
1-lug-2012 Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies Ferroni, P; DELLA MORTE, D; Palmirotta, R; Rundek, T; Guadagni, F; Roselli, M Articolo su rivista
1-gen-2017 Anti-angiogenic drugs, vascular toxicity and thromboembolism in solid cancer Riondino, S; Del Monte, G; Fratangeli, F; Guadagni, F; Roselli, M; Ferroni, P Articolo su rivista
1-gen-2018 Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis Grenga, I; Donahue, Rn; Gargulak, Ml; Lepone, Lm; Roselli, M; Bilusic, M; Schlom, J Articolo su rivista
1-gen-2015 Are there alternative ways to quantify the real benefit of novel agents in oncology? - The 'death pace' Formica, V; Montefusco, E; Roselli, M Articolo su rivista
1-gen-2018 Artificial intelligence for cancer-associated thrombosis risk assessment Ferroni, P; Roselli, M; Zanzotto, Fm; Guadagni, F Articolo su rivista
1-dic-2012 Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer Ferroni, P; Riondino, S; Portarena, I; Formica, V; La Farina, F; Martini, F; Massimiani, G; Palmirotta, R; Guadagni, F; Roselli, M Articolo su rivista
1-gen-2003 Association between serum carcinoembryonic antigen and endothelial cell adhesion molecules in colorectal cancer Roselli, M; Guadagni, F; Martini, F; Spila, A; Mariotti, S; D'Alessandro, R; Aloe, S; Gazzaniga, P; Basili, S; Cosimelli, M; Ferroni, P Articolo su rivista
1-gen-2016 The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy Roselli, M; Formica, V; Cereda, V; Jochems, C; Richards, J; Grenga, I; Orlandi, A; Ferroni, P; Guadagni, F; Schlom, J Articolo su rivista
1-gen-2010 Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxaliplatin-fluoropyrimidine doublet Comella, P; Casaretti, R; Manzo, R; Sandomenico, C; Licenziato, M; Avallone, A; Franco, L; on behalf of the Southern Italy Cooperative Oncology, G; ], [; Roselli, M Articolo su rivista
1-ott-2016 Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: Pros and cons Sini, V; Cassano, A; Corsi, D; De Laurentiis, M; Gamucci, T; Mauri, M; Naso, G; Roselli, M; Ruggeri, E; Tonini, Gmp; Vici, P; Zampa, G; Marchetti, P Articolo su rivista
1-gen-2017 Biological and predictive role of ERCC1 polymorphisms in cancer Formica, V; Doldo, E; Antonetti, F; Nardecchia, A; Ferroni, P; Riondino, S; Morelli, C; Arkenau, H; Guadagni, F; Orlandi, A; Roselli, M Articolo su rivista
1-gen-2005 Biological effects of a software-controlled voltage pulse generator (PhyBack PBK-2C) on the release of vascular endothelial growth factor (VEGF) Ferroni, P; Roselli, M; Guadagni, F; Martini, F; Mariotti, S; Marchitelli, E; Cipriani, C Articolo su rivista
15-lug-2012 Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer Roselli, M; Fernando, R; Guadagni, F; Spila, A; Alessandroni, J; Palmirotta, R; Costarelli, L; Litzinger, M; Hamilton, D; Huang, B; Tucker, J; Tsang, K; Schlom, J; Palena, C Articolo su rivista